Published in Immunology on September 01, 2014
Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Cell (2015) 1.58
Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature (2016) 1.04
Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. J Virol (2015) 1.00
Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J Virol (2014) 0.97
Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. J Virol (2016) 0.84
Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Rep (2016) 0.83
H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination. Immunology (2015) 0.81
Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices. Proc Natl Acad Sci U S A (2016) 0.80
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proc Natl Acad Sci U S A (2016) 0.79
HCV E2 core structures and mAbs: something is still missing. Drug Discov Today (2014) 0.79
Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures. MAbs (2015) 0.79
High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface. MAbs (2014) 0.78
Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein. PLoS One (2016) 0.77
An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction. J Immunol Res (2016) 0.75
Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein. PLoS One (2016) 0.75
Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection. J Virol (2016) 0.75
High-throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. J Virol (2017) 0.75
The Bitter Taste Receptor TAS2R16 Achieves High Specificity and Accommodates Diverse Glycoside Ligands by using a Two-faced Binding Pocket. Sci Rep (2017) 0.75
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
The atomic structure of protein-protein recognition sites. J Mol Biol (1999) 12.63
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Anatomy of hot spots in protein interfaces. J Mol Biol (1998) 9.70
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
The immune epitope database 2.0. Nucleic Acids Res (2009) 6.07
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
Comparison of a structural and a functional epitope. J Mol Biol (1993) 3.12
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol (2004) 2.64
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
Proof of principle for epitope-focused vaccine design. Nature (2014) 2.09
Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit (2007) 2.02
VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure (1998) 2.02
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A (2012) 1.74
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
Computational characterization of B-cell epitopes. Mol Immunol (2007) 1.60
Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs (2007) 1.58
Structural analysis of B-cell epitopes in antibody:protein complexes. Mol Immunol (2012) 1.28
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One (2011) 1.20
Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One (2011) 1.20
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2012) 1.17
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A (2010) 1.11
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One (2009) 1.10
Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc (2009) 1.07
Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology (2010) 1.05
Advances in structure-based vaccine design. Curr Opin Virol (2013) 1.04
Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A (2013) 0.97
Site-Directed Mutagenesis in Epitope Mapping Methods (1996) 0.96
Mapping the epitopes of antibodies. Biotechnol Genet Eng Rev (2007) 0.93
Impact of new sequencing technologies on studies of the human B cell repertoire. Curr Opin Immunol (2013) 0.92
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol (2014) 0.86
Current approaches to fine mapping of antigen-antibody interactions. Immunology (2014) 0.82
Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Vaccine (2009) 0.81
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 2.32
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One (2011) 1.20
Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One (2011) 1.20
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2012) 1.17
Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc (2009) 1.07
Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A (2013) 0.97
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis (2013) 0.94
Virus-like particles as quantitative probes of membrane protein interactions. Biochemistry (2008) 0.86
Cell-free assay of G-protein-coupled receptors using fluorescence polarization. J Biomol Screen (2008) 0.81
Maturation of the Gag core decreases the stability of retroviral lipid membranes. Virology (2012) 0.77
Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors. J Virol (2013) 0.76
Measuring membrane protein interactions using optical biosensors. Methods Mol Biol (2010) 0.75
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight (2017) 0.75